Anika Therapeutics (ANIK) Proxy filing summary

Executive summary

• Achieved $112.8 million in 2025 revenue, driven by OA Pain Management and Commercial Channel growth.

• Generated $11.2 million in operating cash flow and $4.4 million in free cash flow, reflecting improved operational discipline.

• Expanded adoption of the Integrity Implant System and advanced regulatory milestones for Hyalofast and Cingal.

• Completed divestitures of Arthrosurface and Parcus Medical, focusing on HA-based core businesses.

• Strategic priorities for 2026 include accelerating Commercial Channel growth, advancing the HA-based pipeline, and strengthening operational discipline.

Voting matters and shareholder proposals

• Election of three Class III Directors to serve until the 2029 Annual Meeting.

• Ratification of Deloitte & Touche LLP as independent auditor for 2026.

• Advisory “say-on-pay” vote on 2025 executive compensation.

• Approval of amendments to the 2017 Omnibus Incentive Plan and 2021 Employee Stock Purchase Plan, each increasing authorized shares.

Board of directors and corporate governance

• Board consists of nine directors, with a mix of experienced and recently added members; five of nine joined in the past five years.

• 77.8% of directors are independent; board refreshment and diversity are emphasized.

• Separate roles for Executive Chair, Lead Independent Director, and CEO to enhance oversight and continuity.

• Board committees include Audit, Compensation, and Governance and Nominating, all with independent members.

• Annual board and committee evaluations, director overboarding guidelines, and robust stock ownership requirements.